Objective. To analyze outcomes in patients with squamous cell carcinoma (SCCA) of the tonsil from the years 1998 to 2006. To assess factors that may affect disease-specific survival, such as patient characteristics and/or treatment modality.
S quamous cell carcinoma (SCCA) of the tonsil is the most common type of oropharyngeal cancer, 1 with an incidence of 4000 cases per year in the United States. 2 The incidence of tonsillar SCCA has been shown to be increasing in recent years, especially in the younger population, and this may be attributed to increasing rates of human papilloma virus (HPV). 3 Traditional risk factors for oropharyngeal squamous cell carcinoma include tobacco and alcohol use; 4, 5 HPV is a more recently identified risk factor for tonsillar SCCA and has been suggested to confer a better prognosis. 6 This has led some authors to suggest that HPV-positive SCCA is a distinct disease entity, with tumorigenesis occurring through incorporation of viral genes leading to degradation of tumor suppressor genes such as p53. 7 Changing patterns in the incidence and outcomes of tonsillar SCCA lend themselves to populationbased studies, such as use of the Surveillance, Epidemiology and End Results (SEER) database.
Early-stage tonsillar SCCA is treated with single-modality therapy, either surgery or radiation, with similar outcomes. 8 In recent years, however, there has been an evolution of treatment modalities for more advanced tonsillar SCCA. Whereas advanced cases traditionally were treated with surgery and adjuvant radiation, randomized control trials have made concurrent chemoradiation for advanced tonsillar SCCA a viable primary treatment modality. 9, 10 Moreover, surgical techniques have progressed, with new approaches such as transoral laser microsurgery (TLM). 11 Over the past decade, radiation techniques have also changed-namely, there has been increasing use of intensitymodulated radiation therapy (IMRT), a conformal technique that allows high doses of radiation to the target tissues while sparing adjacent healthy tissues. 12 There also has been refinement of radiation techniques used for head and neck SCCA, such as the use of image-guided radiation therapy (IGRT) with cone-beam computerized tomography (CT) scanning. 13 Both the changing patient profile and the advances being made in methods of treatment may affect outcomes for patients with tonsillar SCCA. The hypothesis of the current study was that these factors would lead to improved patient outcomes in more recent years. Specifically, we wondered whether progress in radiation techniques would lead to improvement in disease-specific survival for patients treated with external beam radiation.
Methods
Using the National Cancer Institute SEER database, we performed a population-based cohort analysis for patients diagnosed with SCCA of the tonsil from 1998 to 2006. Because the database used contains publicly available information and no personal identifiers, the study did not require approval of the internal review board. Patients were identified from the SEER 17 registries (Alaska Natives, Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, rural Georgia, Utah, greater California, Kentucky, Louisiana, and New Jersey), which represent 26% of the US population and are demographically matched to the US population. 14 Incident cases of tonsillar squamous cell carcinoma were obtained from the SEER database, including histopathology of "squamous cell carcinoma, not otherwise specified," and anatomic sites coded as "tonsil, not otherwise specified," "tonsillar fossa," "tonsillar pillar," and "overlapping lesion of tonsil." Patient characteristics included in the analysis were gender, ethnicity, age, year of diagnosis, and treatment with radiation and/or surgery. Recorded tumor staging was not consistent over the study time period, because the most recent version of the tumor, node, metastasis (TNM) staging system became effective in January 2003, and so was not included in this analysis.
For ease of statistical analysis, treatments were divided into several categories. Patients receiving external beam radiation were compared with those not receiving radiation, and cases with unknown radiation status or implants/isotopes were excluded. Furthermore, surgery was categorized into 4 categories based on the extent of surgical resection, including no surgical intervention, local tumor excision (including biopsy), limited or partial pharyngectomy, and more extensive pharyngectomy including mandibulectomy and/or laryngectomy. Diseasespecific death was determined by a survival analysis according to a field termed "vital status relative to site at dx" or "SEER causespecific death classification." All data was analyzed using the SEER*Stat version 6.5.2 (Bethesda, Maryland).
The goal of the statistical analysis was to evaluate the relationships between the predictors of sex, age, ethnicity, year of diagnosis, and treatment modality with the outcome of disease-specific survival time. This analysis was performed using Cox proportional hazards (Cox-PH) regression models. Initially, singlepredictor Cox-PH models were constructed to examine the effect of each predictor on survival time. Next, we constructed a multiple Cox-PH model using all the predictors. Finally, we constructed a separate Cox-PH model including the year by radiation interaction effect to study whether the impact of radiation use differed over time. Disease-specific survival curves were plotted using the Kaplan-Meier method. Two-year survival proportions were estimated on the basis of the Kaplan-Meier curves.
Results
Applied inclusion criteria for the SEER database search resulted in 8378 patients. Of this patient cohort, 80% were male and 85% were white. The mean patient age at diagnosis was 58.1 years ( Table 1) . External beam radiation with or without surgery was used to treat 78.9% of patients. Treatment summaries divided those patients treated with and without external beam radiation and those with different extents of surgery ( Table 2) . On univariate analysis, males had significantly lower disease-specific survival than females (hazard ratio [HR] = 0.93, P = .006). Ethnicities other than white carried a significantly higher rate of disease-specific death (HR = 1.71, P < .001). Each additional year of age at the time of diagnosis carried approximately a 4% increase in likelihood of diseasespecific death (HR = 1.04, P < .001). Patients who underwent radiation therapy had significantly better disease-free survival than those who did not (HR = 1.9, P < .001). Patients with more extensive surgical resection (with categories of no surgical intervention, local tumor excision, limited or partial pharyngectomy, and more extensive pharyngectomy including mandibulectomy and/or laryngectomy) also had a significantly higher disease-free survival than those with less extensive resection (HR = 0.62, P < .001).
On multiple Cox-PH model with and without interaction effect, patient gender did not significantly affect disease-free survival. For other variables, the multiple Cox-PH model showed similar trends as the univariate analysis, with significant differences in disease-free survival based on patient age (HR = 1.03, P < .001), ethnicity (HR = 1.52, P < .001), radiation treatment (HR = 2.04, P < .001), and extent of surgery (HR = 0.65, P < .001). Kaplan-Meier curves demonstrating these findings are illustrated in Figures 1 through 4 , respectively.
As discussed in the introduction, a multiple Cox-PH model with an interaction effect was completed to analyze the possible difference between outcomes of patients receiving radiation therapy (XRT) in subsequent years. Similar to the multiple Cox-PH model without interaction effect, there were significant differences observed in disease-free survival based on patient age (HR = 1.03, P < .001), ethnicity (HR = 1.53, P < .001), and extent of surgery (HR = 0.65, P < .001). Moreover, the interaction effect demonstrates that the difference in survival time between those patients with and without radiation is increasing over time (Figure 5) . During the period 1998 to 2000, the 2-year survival rates were 68% (no XRT) versus 77% (with XRT); for 2001 to 2003 they were 65% (no XRT) versus 79% (with XRT), and for 2004-2005 they were 63% (no XRT) versus 83% (with XRT). The relative proportion of the population that received radiation was unchanged across the years.
Overall patient mortality was examined by year of diagnosis. With each passing year of time at diagnosis, patients carried a decreased risk of disease-specific death (P < .001); this value was significant in all 3 statistical models (Figure 6) . This effect is best illustrated when the study time period is divided into 2-year categories (Figure 7) .
Discussion
The increasing incidence of tonsillar SCCA make it a growing public health concern in the United States. The rates of tonsillar SCCA are increasing predominantly in the younger patient population; this trend has been attributed to higher rates of HPV in this group. 3 Nguyen et al 15 demonstrated that HPVpositive tonsillar SCCA is more common in the 30-to 50-year age group, whereas HPV-negative tonsillar SCCA is more common in the 50-to 70-year age group. 15 The current study showed a marked trend of increased survival among younger patients versus older patients (Figure 1) . This trend may be attributable in part to the relative lack of comorbidities in younger patients; however, it is also consistent with other studies that have demonstrated increased relative survival among patients with HPV-positive tonsillar SCCA. 16, 17 The current study also found that ethnicities other than white demonstrated a significantly decreased disease-specific survival. Although it has been demonstrated by matched-pair analysis that African American, Hispanic, and white patients have similar outcomes when they receive similar care, 18 ethnicity cannot be separated from socioeconomic status in this study. Previous reports have shown that patients at public hospitals have similar but delayed treatment as those in academic centers and that this can lead to worse outcomes. 19 Access to care remains paramount for early diagnosis and treatment in optimizing outcomes for head and neck cancer. 20 Moreover, outcomes of tonsillar carcinoma in particular may be affected by the different rates of HPV among different ethnic groups. 21 This study also suggests differences in patient outcome according to treatment modalities; however, these results must be interpreted with caution because limitations of the data entered into the SEER database did not allow survival analysis by stage. In general, patients receiving external beam radiation had longer disease-specific survival than those who did not. This phenomenon could be explained by the following. First, primary radiation is often used in single-modality therapy for early-stage SCCA of the tonsil 8 -this improved outcome could be attributable to less advanced disease at diagnosis. Also, patients who received radiation may have received it after surgery. Many patients are diagnosed with tonsillar cancer by tonsillectomy-some of these patients receive radiation as primary treatment for their disease because tonsillectomy without margins is viewed as a "biopsy" by the treating physician. 22 The other benefit of radiation over nonradiation could be attributed to patients who did not follow through with recommended postoperative radiation or those who were otherwise thwarted when adjuvant radiation was indicated after surgery. Furthermore, as hypothesized, the difference in disease-free survival between radiated and nonradiated patients increased over time in the current study ( Figure  5 ). If this phenomenon is borne out in future studies that include staging information, it could be explained by increases in the use of IMRT and improved radiotherapy techniques. In fact, Jaber et al 23 directly related changes in radiation techniques to changes in disease-free survival in a study of 683 veterans. Although improvements in treatment modalities such as external beam radiation certainly may affect diseasespecific survival, a study including further stratification of patients by stage is necessary to make conclusions about the use of specific therapies. Interestingly, the extent of surgery had a complicated effect on disease-free survival when analyzed by multivariate analysis (Figure 4) . Those patients with no surgery and those with maximal surgery (meaning tonsillectomy and pharyngectomy, including mandibulectomy and/or laryngectomy) did worse than those patients who underwent minimal surgery (meaning local tumor excision) and those with moderate surgery (meaning those with tonsillectomy and pharyngectomy without mandibulectomy or laryngectomy). This finding can be explained by extent of surgery being a proxy for extent of disease. It is probable that those patients with no surgery and maximal surgery were more likely to have advanced disease, whereas those with minimal and moderate surgery were more likely to have early disease. We expect that disease-specific survival differences according to extent of surgery will continue to change as some centers move away from traditional approaches toward advanced tonsillar SCCA including mandibulectomy, transoral radical tonsillectomy techniques, 24 and transoral robotic surgery. 25 Finally, the current study found that overall diseasespecific survival is increasing for tonsillar SCCA over time (Figure 6) . This finding is likely attributable, in part, to the improved survival of HPV-positive patients and the increased incidence of this patient population. Moreover, improvement in treatment modalities, including improved radiotherapy techniques 12 and the advent of concurrent chemoradiation for advanced cases, 26 may have led to improved treatment outcomes. Although this finding of improved outcome is statistically significant, it is not completely linear and so is best illustrated by 2-year groupings of disease-free survival (Figure 7) .
Although the strength of the current study lies in the large number of patients included, which tends to minimize confounding factors, the study has several limitations that should be recognized. First, our findings are only as reliable as the data that are entered in the SEER database-inherent error in this system may lead to spurious results. Second, the definition of radiotherapy treatment included in the SEER database is not specific because it also includes palliative radiation treatment, and this confounder has been cited by other authors. 6 Third, we did not include staging data or chemotherapy data, as these factors were not consistently recorded throughout our study time period. As discussed earlier, staging information is particularly important to glean information about response to different treatment modalities. Finally, although the improved survival over time can be attributed to an increase in HPV-positive cases and changes in surgical and radiotherapy techniques, the details of these changes are not specified in the SEER database.
In conclusion, we may be making a difference in outcomes in tonsillar SCCA; at least, outcomes are improving over time. Whether due to an increase in less aggressive HPV-associated carcinomas or better options for managing the disease, diseasespecific survival for squamous cell carcinoma of the tonsil has increased in recent years.
